These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 14518558)

  • 1. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy.
    Celotti F; Durand T
    Prostaglandins Other Lipid Mediat; 2003 Jul; 71(3-4):147-62. PubMed ID: 14518558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?
    Fiorucci S; Meli R; Bucci M; Cirino G
    Biochem Pharmacol; 2001 Dec; 62(11):1433-8. PubMed ID: 11728379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis.
    Alvaro-Gracia JM
    Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i21-5. PubMed ID: 14752172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is licofelone, a dual inhibitor of cyclo-oxygenase and 5-lipoxygenase, a promising alternative in anti-inflammatory therapy?
    Bannwarth B
    Fundam Clin Pharmacol; 2004 Feb; 18(1):125-30. PubMed ID: 14748764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks.
    Bertolini A; Ottani A; Sandrini M
    Curr Med Chem; 2002 May; 9(10):1033-43. PubMed ID: 12733982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial.
    Bias P; Buchner A; Klesser B; Laufer S
    Am J Gastroenterol; 2004 Apr; 99(4):611-8. PubMed ID: 15089890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors.
    de Gaetano G; Donati MB; Cerletti C
    Trends Pharmacol Sci; 2003 May; 24(5):245-52. PubMed ID: 12767724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs.
    Charlier C; Michaux C
    Eur J Med Chem; 2003; 38(7-8):645-59. PubMed ID: 12932896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of anti-inflammatory treatment--new ways of thinking.
    Brune K
    Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i16-20. PubMed ID: 14752171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept.
    Celotti F; Laufer S
    Pharmacol Res; 2001 May; 43(5):429-36. PubMed ID: 11394934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of cyclo-oxygenases and 5-lipoxygenase: a novel therapeutic approach to inflammation?
    Naveau B
    Joint Bone Spine; 2005 May; 72(3):199-201. PubMed ID: 15850989
    [No Abstract]   [Full Text] [Related]  

  • 13. COX-LOX inhibition: current evidence for an emerging new therapy.
    Skelly MM; Hawkey CJ
    Int J Clin Pract; 2003 May; 57(4):301-4. PubMed ID: 12800462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastroprotective and ulcer healing effects of nitric oxide-releasing non-steroidal anti-inflammatory drugs.
    Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Drozdowicz D; Kwiecień S; Pajdo R; Ptak A; Pawlik M; Hahn E
    Dig Liver Dis; 2000 Oct; 32(7):583-94. PubMed ID: 11142556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept.
    Gaddi A; Cicero AF; Pedro EJ
    Arch Gerontol Geriatr; 2004; 38(3):201-12. PubMed ID: 15066307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
    Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
    JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
    Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
    Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases.
    Pelletier JP; Boileau C; Boily M; Brunet J; Mineau F; Geng C; Reboul P; Laufer S; Lajeunesse D; Martel-Pelletier J
    Arthritis Res Ther; 2005; 7(5):R1091-102. PubMed ID: 16207326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA; Weir MR
    Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.